Philadelphia chromosomeelike acute lymphoblastic leukemia (Ph-like ALL) is a recently described B-cell precursor ALL with a gene expression profile and a high frequency of IKZF1 gene alteration similar to that of Ph-positive ALL. Its prevalence is approximately 12% in children, 21% in adolescents (16-20 years of age), and 20% to 24% in adults older than 40 years, with a peak (27%) in young adults 21 to 39 years old. It occurs more often in male individuals and patients with Down syndrome. Ph-like ALL is overrepresented in those with Hispanic ethnicity and is associated with inherited genetic variants in GATA3 (rs3824662). It is a clinically and biologically heterogeneous subtype of B-ALL. Although most patients with Ph-like ALL have positive minimal residual disease after remission induction and poor event-free survival, approximately 40% of pediatric patients responded well to chemotherapy and can be cured with relatively low intensity of treatment. The treatment outcome correlated negatively with increasing age at presentation. Ph-like ALL is characterized by a wide range of genetic alterations that dysregulate several cytokine receptor and kinase signaling pathways, including CRLF2 rearrangement in half of the cases and translocation of nonreceptor tyrosine kinases (predominantly ABL-class and Janus kinases). Patients with ABL-class fusions respond clinically to ABL1 tyrosine kinase inhibitors, whereas mutations activating the JAK-STAT pathway are amendable to treatment with JAK inhibitors in vitro or in preclinical models. Prospective studies are needed to determine if incorporation of tyrosine kinase inhibitor targeting kinase alterations into intensive chemotherapy regimens will improve outcome of patients with Ph-like ALL.
Introduction
Based on gene expression profiling studies of B-cell precursor ALL (B-ALL), Philadelphia chromosome (Ph)-like (also known as BCR-ABL1-like) acute lymphoblastic leukemia (ALL) was independently identified by 2 groups of investigators in 2009: the Children's Oncology Group (COG)-TARGET-St. Jude consortium and the Dutch Childhood Oncology Group. 1, 2 This subtype of B-ALL has a gene expression profile similar to that of Ph-positive ALL but lacks the BCR-ABL1 fusion protein expressed from t(9;22)(q34.1;q11.2), and was associated with unfavorable clinical outcome when treated with conventional chemotherapy. 1,2 Like
Ph-positive ALL, 3 Ph-like ALL cases also have a high frequency of genetic alterations of IKZF1, which encodes the lymphoid transcription factor Ikaros. 1, 2 Such alterations are associated with poor outcome in both Ph-positive and Ph-negative ALL, 4 in part by dysregulating adhesion of and mislocalizing leukemic cells in the bone marrow niche. 5 All subsequent pediatric and adult studies have shown that this subtype of ALL is associated with dismal outcome, [6] [7] [8] [9] [10] [11] [12] [13] with the exception of St. Jude Total Therapy Study XV, which was the first clinical trial to use minimal residual disease (MRD) levels prospectively during and after remission induction therapy to guide risk-directed treatment, which attenuated the poor prognosis of Ph-like ALL despite its association with high MRD levels 14 (Table 1) . We here review the recent advances in the clinical overlapping, but not identical, subset of cases. 1, 2, 15 The COG-TARGET-St. Jude consortium first identified a subset of IKZF1-altered, high-risk B-ALL cases with a gene expression profile similar to Ph-positive ALL using Gene Set Enrichment Analysis, 1 and subsequently used prediction analysis of microarrays of Affymetrix gene expression microarray data of high-risk B-ALL to identify 257 gene probe sets that defined Ph-positive and Ph-like cases. 16 Genetic alterations deregulating cytokine receptor and tyrosine kinase genes, and deletions or mutations of the lymphoid transcription factor gene IKZF1 (encoding Ikaros) are a hallmark of the subtype defined by this classifier. By contrast, the signature of Den Boer et al 2 was
based on hierarchical clustering of 110 probe sets identified to predict other major pediatric ALL subtypes (T-cell, ETV6-RUNX1, high hyperdiploid, TCF3-PBX1, MLL-rearranged, and BCR-ABL1). Ph-like ALL defined by this signature had frequent deletions in B-cell development genes (eg, IKZF1), dic(9;20), and intrachromosomal amplification of chromosome 21. 2, 7, 15 Both signatures identified molecularly distinct but overlapping groups of patients with poor prognosis, but shared only 9 overlapping probe sets of 7 genes (CCND2, SH3BP5, ABL1, SOCS2, DUSP6, LST1, EGFL7). 15 Importantly, tyrosine kinase fusion genes involving ABL1, PDGFRB, and JAK2 were found only in patients with Ph-like ALL using the classifier of COG-TARGET-St. Jude consortium. 15 Subsequently, the COG have developed a targeted lowdensity array that quantitates expression of 8 to 15 genes that are overexpressed in Ph-like ALL. 12 These probe sets, and the statistical algorithm used to convert raw gene expression data into a single numerical score predictive of Ph-like ALL, were selected and derived using large cohorts of cases with comprehensive genomic characterization. Thus, different clustering, prediction, and quantitative polymerase chain reaction (PCR) approaches have been used that result in inconsistent predictions, and this may result in confusion regarding the optimal approach to identify patients with Ph-like ALL. It is emphasized that the most consistent, robust predictions are obtained when gene expression prediction approaches are trained and applied using data from the same center and technical platforms; and that the approaches used must be shown to sensitively and reproducibly identify all kinase-activating alterations in Ph-like ALL.
Prevalence and Clinical Features
The prevalence of Ph-like ALL differs by age, gender, race, ethnicity, and National Cancer Institute (NCI)-defined risk groups. It comprises approximately 12% of children with B-cell precursor ALL (10% of NCI standard-risk and 13%-14% of NCI high-risk B-ALL), 21% of adolescents 16 to 20 years old, 27% of young adults 21 to 39 years old, and 20% to 24% of adults older than 40 years 8, [11] [12] [13] (Table 1) . Compared with Ph-positive ALL, the prevalence of Ph-like ALL is 3 to 4 times more common in children and approximately the same as that in adults. A higher proportion of patients with Ph-like ALL are male patients compared with those with nonePh-like B-ALL in both children and adults with a maleto-female ratio of 2.0:1.0 and 1.6:1.0, respectively. 8, 12, 14 Hispanic patients have been shown to have a higher prevalence of Ph-like ALL, with a particular preponderance of CRLF2 rearrangements. 13, 17 This is in part explained by the higher frequency of germline Ph-like ALL risk variant in GATA3 (rs3824662) in Hispanic individuals with Native American genetic ancestry. 18 This germline GATA3 single nucleotide polymorphism was also associated with high MRD at the end of remission induction and increased risk of relapse, a finding consistent with ancestry-related disparities in ALL treatment outcomes. 19 Studies of pediatric Ph-like ALL have been conducted largely in patients with high-risk ALL with one exception, which was performed among consecutive patients treated in the St. Jude Total XV study.
14 The St. Jude study clearly showed that none of cases with a Ph-like gene expression profile had t(1;19)/TCF3-PBX1, t(4;11)/KMT2A-AFF1, or t(12;21)/ETV6-RUNX1, but the proportion of hyperdiploidy with more than 50 chromosomes did not differ significantly between the 40 patients with Ph-like ALL and the 304 patients with nonePh-like B-ALL. 14 In the St. Jude study, the median age and median presenting leukocyte count did not differ significantly between patients with Ph-like and nonePh-like ALL, and hence there was no significant difference in the distribution of NCI-defined risk groups (based on age and presenting leukocyte count). 14 Compared with nonePh-like B-ALL, patients
with Ph-like ALL were more likely to be male, have Down syndrome, and have higher MRD during and after remission induction; because of the MRD results, a significantly higher proportion of patients with Ph-like ALL received intensive postremission treatment (60% vs. 41%). 14 In a recent large multicenter study of 798 adult patients with B-ALL, the 194 patients with Ph-like ALL were more likely to be male and have significantly higher median presenting leukocyte count (56.6 vs. 26.8 Â 10 9 /L) than those with nonePh-like B-ALL (excluding Ph-positive and KMT2A-rearranged ALL).
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In virtually all pediatric and adult studies, Ph-like ALL was associated with increased MRD levels after remission induction and poor overall outcome (Table 1) .
1,2,6-13 In fact, in each age group, patients with Ph-like ALL had inferior outcome as compared with those with nonePh-like ALL. Of interest, in the St. Jude Total Therapy study XV, which featured MRD-directed treatment, the 40 patients with Ph-like ALL and the other 304 patients with nonePhlike B-ALL had the same overall 5-year event-free survival (90% AE 4.7% vs. 88.4% AE 1.9%) and 5-year overall survival (92.5% AE 4.2% vs. 95.1% AE 1.3%). 14 There was no significant difference in outcome between the 2 groups of patients in each of the 3 risk groups based on the MRD levels, albeit a higher proportion of patients with Ph-like ALL underwent allogeneic transplantation due to a high level of MRD (! 1%) at the end of remission induction, as compared with patients with nonePh-like B-ALL (15% vs. 5%). 14 Similar to Ph-positive ALL, the outcome of Ph-like ALL correlated negatively with increasing age: children fared better than adolescents who in turn have superior outcome than young adults, and older adults have the worst outcome 8, 12 (Table 1) .
Biologic Features and Genomic Landscape
In contrast to many ALL genetic subtypes that have a single founding chromosomal rearrangement that results in deregulated expression of an oncogene or expression of a fusion oncoprotein, genome and transcriptome sequencing studies have shown Ph-like ALL to have a complex genomic landscape with diverse genetic alterations that dysregulate several classes of cytokine receptors and tyrosine kinases (Figure 1) . 20 Similar to Ph-positive ALL, a hallmark of Ph-like ALL is the high frequency of IKZF1 alterations (70%-80%) as compared with nonePh-like ALL (15%). 8, 12, 20 Several classes of kinase-activating alterations have been described. These include alterations activating JAK-STAT signaling (involving CRLF2, JAK2, EPOR, and other genes in this pathway), ABL-class fusions (ABL1, ABL2, CSF1R, PDGFRA, and PDGFRB), Ras pathway mutations (KRAS, NRAS, NF1, PTPN11), and uncommon fusions (NTRK3, PTK2B, BLNK ) 8, 12, 20 ( Figure 1 , Table 2 ). Only a small subset of patients did not have a kinaseactivating alteration identified by transcriptome analysis. The largest class of kinase-activating lesions are those resulting in activation of JAK-STAT signaling. Of these, most are rearrangements or point mutations of CRLF2. Approximately half of the Ph-like cases harbor rearrangement of the cytokine receptor CRLF2 (cytokine receptorelike factor 2), either as a translocation to the immunoglobulin heavy chain enhancer region (IGH-CRLF2) or as a focal deletion resulting in the expression of P2RY8-CRLF2 fusion transcript. 21, 22 Both result in expression of full-length CRLF2, which heterodimerizes with interleukin-7 receptor alpha (IL7RA) to form the receptor for thymic stromal lymphopoietin (TSLP). Less frequently, sequence mutations of CRLF2 are present (most commonly p.Phe232Cys) that result in dimerization of CRLF2. Among childhood and adolescent patients with CRLF2 rearrangement, approximately half have concomitant activating mutations of the Janus kinase genes, JAK1 or JAK2, resulting in the activation of JAK-STAT signaling. [21] [22] [23] In adults, the frequency of JAK mutations in patients with CRLF2 rearrangement is lower, with a ratio of 1:4 with JAK wild-type ( Figure 1 ). Mutations in IL7R and SH2B3 have also been identified in patients with CRLF2 alterations that lack JAK mutations, indicating these lesions may cooperate with CRLF2 overexpression to induce leukemogenesis. 8 Several other genetic alterations activate JAK-STAT signaling. These include rearrangements of JAK2 and EPOR (encoding the erythropoietin receptor), which account for approximately 7% and 5% of Ph-like ALL cases, respectively. 12, 20 At least 19 different JAK2 fusions have been identified, each of which result in expression of a chimeric fusion gene with preservation of the JAK2 kinase domain. The prevalence of JAK2 fusions is similar between the different age groups (Figure 1 ). 8, 12 Five types of EPOR rearrangements have been identified.
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The most common involved juxtaposition or translocation of the EPOR gene to the enhancer regions of immunoglobulin heavy or kappa loci, leading to the deregulated expression of a truncated form of the EPOR gene that has been shown to drive leukemogenesis. 24 Less frequent mechanisms involve insertion and truncation of EPOR into the upstream region of LAIR1 or the THADA loci. The frequency of EPOR rearrangements appear to be twofold higher in young adults (9%) compared with children and adolescents (5% and 3%, respectively), and less frequent in adults older than 40 (1%; Figure 1 ). JAK2 rearrangements lead to constitutive activation of JAK-STAT signaling, whereas the EPOR rearrangements result in stabilized expression of the erythropoietin receptor on the surface of B-cells, with failure of receptor downregulation and heightened JAK-STAT signaling in response to ligand (EPO) stimulation. In both contexts, the abnormal JAK-STAT signaling can be abrogated by the use of JAK inhibitors, such as ruxolitinib, as has been
Ph-like ALL demonstrated in vitro in cell line models, and in preclinical xenograft models. 16, 24, 25 An additional subset of Ph-like patients has a range of sequence mutations and DNA copy number alterations (but without rearrangements of kinase or cytokine receptor genes) that activate the JAK-STAT pathway (JAK1, JAK3, IL7R, SH2B3, IL2RB, TYK2). SH2B3 (LNK) encodes a negative regulator of JAK-STAT, and deletion of this gene leads to activation of the JAK-STAT pathway. Collectively these alterations were approximately twofold higher in children (14%) compared with adolescents (5.0%), and adults (7.3%). 8, 20 Notably, these cases with mutations/deletions activating JAK-STAT signaling that lack a kinase-activating rearrangement frequently have chromosomal rearrangements resulting in the formation of fusion oncoproteins involving transcription factor genes (EBF1, PAX5, ETV6) and/or epigenetic regulators (CREBBP, SETD2, ASXL1). In these cases, the kinase mutations are commonly multi-/subclonal, indicating they are secondary driving events arising after the founding chromosomal rearrangement. These cases also have a lower frequency of IKZF1 alteration, and a lower Ph-like gene expression coefficient on TLDA prediction analysis, suggesting these may represent a distinct subset of Ph-like ALL.
Approximately 10% of the Ph-like patients (17% in children, 9% in adolescents, 10% young adults, and 9% older adults) have ABLclass gene fusions. 8, 12, 20 The kinases that are rearranged in this subset of Ph-like ALL (ABL1, ABL2, CSF1R, PDGFRA, PDGFRB) are termed "ABL-class" in view of the ability of ABL1 inhibitors such as imatinib and dasatinib to inhibit the downstream signaling induced by each of the chimeric fusion proteins. 8, 16 Multiple fusion partners have been identified in each of the ABLclass genes, and in each instance the fusion involved the kinase as the downstream partner, thus preserving the kinase domain. 12, 20 Another 4% of Ph-like cases have mutations of genes (KRAS, NRAS, NF1, PTPN11, and CBL1) that activate Ras signaling 12, 20 ;
however, it should be noted that these Ras-activating mutations also can be observed in hyperdiploid, hypodiploid, KMT2A-rearranged, and relapsed ALL. [26] [27] [28] Finally, several other rare kinase alterations involving NTRK3, BLNK, PTK2B, and TYK2 have also been identified in Ph-like ALL. 8, 12, 20 Although relatively rare, identification and modeling of these uncommon fusions is important, as they are amenable to targeting with different tyrosine kinase inhibitors than JAK-STAT/ABL-class Ph-like ALL. Additional new rearrangements of other genes will most certainly be identified in future studies. 
Diagnostic Considerations
The heterogeneous genomic landscape and the diverse array of targetable kinase-activating lesions of Ph-like ALL have created a diagnostic dilemma and challenge for most hematopathologists and oncologists. Currently, pediatric study groups and centers have adopted different strategies to diagnose and to characterize Ph-like ALL based on the geographic structure of clinical trials, number of patients to be tested, availability of genome/transcriptome sequencing infrastructure, and clinical goal. Broadly, these approaches range between comprehensive sequencing of all patients at diagnosis irrespective of Ph-like status (the St. Jude approach), to tiered algorithms that first identify Ph-like ALL using TaqMan lowdensity array screening followed by sequential genomic profiling (the COG approach), and focused fusion/gene panel testing. Although each approach has its merits, the optimal strategy is critically dependent on the clinical requirement (eg, identification of all Ph-like patients and comprehensive genomic characterization vs. identification of those with ABL-class lesions only).
The COG has established an algorithm to evaluate all newly diagnosed high-risk B-ALL. 29 They first use a validated TaqMan low-density array card to screen for the Ph-like ALL gene signature. 30 Patients positive for Ph-like ALL (excluding BCR-ABL1 or ETV6-RUNX1 fusion-positive patients), are then stratified by CRLF2 expression. Those with high CRLF2 expression are tested for CRLF2 rearrangement by fluorescence in situ hybridization and JAK1/JAK2 mutation by Sanger sequencing. Patients with low CRLF2 expression are assayed for other kinase alterations by reverse transcription PCR (RT-PCR) and subsequent transcriptome sequencing if negative by PCR. Our recent study of adults also used a similar approach to define the frequency of Ph-like ALL and spectrum of kinase alterations in this population. 12 The UK Medical Research Council screens patients who have poor early treatment response as defined by induction failure, positive MRD on day 14, or persistent MRD at week 14 for ABL-class fusion. 31 Although it is effective for research, this approach may delay identification of patients with kinase lesion for treatment with tyrosine kinase inhibitor during remission induction. At St. Jude, we will complete RNA-seq within the first 2 weeks of remission induction so that most patients with targetable fusion transcripts can be identified to receive tyrosine kinase inhibitor and attain a solid remission, and then complete whole genome and whole exome sequencing to identify full repertoire of kinase alterations by the end of remission induction (day 42).
Other approaches include digital molecular barcoding platform NanoString that can multiplex more than 200 different genetic alterations, or Capture-based RNA sequencing (eg, Archer FusionPlex Oncology Research Kit; Foundation One Heme, Foundation Medicine). 12 One may also choose to perform fluorescence in situ hybridization to assess for break apart of key kinase genes, multiplex RT-PCR, or next-generation sequencing techniques in selected patients (eg, those with a high level of MRD after remission induction), with the ultimate goal to improve outcome by identifying targetable kinase lesions.
Therapeutic Opportunities
The excellent overall 5-year event-free survival of 90.0% AE 4.7% achieved for patients with Ph-like ALL in the Total XV study 14 suggested that MRD-directed treatment should be applied to patients with Ph-like ALL. However, it should be noted that the underlying genomic alterations in our patients with Ph-like ALL may be different from those reported for other high-risk cohorts, particularly with respect to the frequency of CRLF2 rearrangements (28% in the Total XV study compared with 50% in other series), which are associated with poor prognosis, 21, 22 perhaps due to the reduced number of Hispanic patients treated at St. Jude. We observed a similar frequency of ABL-class fusions, but did not identify any JAK2 or EPOR rearrangements, which are also associated with a higher risk of relapse. 8 Nonetheless, we still observed higher MRD levels after remission induction in our Ph-like patients as compared with those of patients with nonePh-like ALL. We attributed our success in treating patients with Ph-like ALL to MRD-directed treatment such that poor responders received intensified treatment, including hematopoietic cell transplantation in 15% of the patients. It is also emphasized that 40% of patients treated on St. Jude Total Therapy XV actually had low-risk leukemia based on negative MRD at the end of induction, and they had 5-year event-free survival of 100% despite receiving relatively low intensity of treatment. Notwithstanding this result, one-third of the transplanted patients relapsed, and the addition of targeted therapy could have prevented relapse or spared some of them from transplantation. Anecdotal reports have shown that patients with refractory Ph-like ALL harboring ABL-class fusion had sustained remission Ph-like ALL after ABL inhibitors. 8, [31] [32] [33] Based on the recent improvement of outcome of Ph-positive ALL with the addition of an ABL inhibitor, 34, 35 there is a strong rationale to conduct the same prospective studies in Ph-like ALL incorporating chemotherapy with appropriately targeted therapy based on the types of kinase lesions (Table 2) . Although ABL1-class and JAK-STAT alterations account for most Ph-like ALL cases, there are several alterations involving kinases that are not inhibited by ABL-class nor JAK inhibitors (eg, BLNK, NTRK3, and TYK2). Future studies are required to assess the potential for targeted inhibitors of these kinases in model systems and human leukemic cells.
Conclusions and Future Perspective
Ph-like ALL is a newly described subtype of B-cell precursor ALL characterized by gene expression profile similar to that of Ph-positive ALL with frequent IKZF1 alterations (70%-80%) but lack the BCR-ABL1 fusion gene. The prevalence varies with age, from 12% in children to 21% in adolescents, 20% to 24% in older adults, and as high as 27% in young adults. Even though Ph-like ALL is associated with poor outcome, given the heterogeneity of treatment response, we recommend MRD-directed treatment to avoid over-or undertreatment and to use available techniques, preferably next-generation sequencing platform, to screen for genetic lesions that are amendable to treatment with currently available tyrosine kinase inhibitors, such as ABL-class or JAK inhibitors. Global collaboration will be needed to determine the optimal treatment for patients with other rare kinase alterations, such as Ras, NTRK3, PTK2B, and TYK2. To this end, MEK inhibition has shown some promise in targeting downstream Ras pathway, 28 and the specific TRK inhibitor, LOXO-101, effectively inhibited the ETV6-NTRK3 translocation in preclinical models. 36 Finally, future studies also should focus on the mechanism of drug resistance to kinase inhibitors so that therapeutic intervention can be developed. For example, retinoids and focal adhesion kinase inhibitors can potentiate the activity of dasatinib in mouse and human BCR-ABL1 ALL with IKZF1 mutation, 5, 37 and ponatinib induced a transient remission in a case with ABL1 kinase domain mutation T315I after initial response to dasatinib. 38 
